Update data/rag/knowledge_base/Cryptococcus/gattii.json
Browse files
data/rag/knowledge_base/Cryptococcus/gattii.json
CHANGED
|
@@ -0,0 +1,52 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
{
|
| 2 |
+
"genus": "Cryptococcus",
|
| 3 |
+
"species": "gattii",
|
| 4 |
+
"full_name": "Cryptococcus gattii",
|
| 5 |
+
"clinical_significance": "A highly virulent Cryptococcus species complex that infects immunocompetent hosts. Often causes large pulmonary or CNS cryptococcomas, and outbreaks have occurred in Canada, the U.S. Pacific Northwest, and Australia.",
|
| 6 |
+
"phenotype_profile": {
|
| 7 |
+
"morphology": "Encapsulated yeast; often features a larger and more robust capsule than C. neoformans.",
|
| 8 |
+
"culture": "Mucoid colonies; blue coloration on CGB (L-canavanine–glycine–bromothymol blue) medium due to ability to utilize glycine.",
|
| 9 |
+
"biochemical": [
|
| 10 |
+
"Urease positive",
|
| 11 |
+
"Phenol oxidase positive",
|
| 12 |
+
"Grows at 37 °C",
|
| 13 |
+
"Positive on CGB agar (turns medium blue)",
|
| 14 |
+
"No pseudohyphae",
|
| 15 |
+
"Strong melanin production"
|
| 16 |
+
]
|
| 17 |
+
},
|
| 18 |
+
"differentiation": {
|
| 19 |
+
"from close species": [
|
| 20 |
+
"Blue color change on CGB agar is highly specific for C. gattii.",
|
| 21 |
+
"More frequent disease in immunocompetent hosts vs. C. neoformans.",
|
| 22 |
+
"Associated with tree habitats (eucalyptus, rainforest species)."
|
| 23 |
+
],
|
| 24 |
+
"from other genera": [
|
| 25 |
+
"Melanin-producing, encapsulated, but CGB-positive profile is unique."
|
| 26 |
+
]
|
| 27 |
+
},
|
| 28 |
+
"virulence_factors": [
|
| 29 |
+
"Large polysaccharide capsule",
|
| 30 |
+
"Melanin production",
|
| 31 |
+
"Ability to form large cryptococcomas",
|
| 32 |
+
"Survival and replication in macrophages",
|
| 33 |
+
"Enhanced resistance to oxidative stress"
|
| 34 |
+
],
|
| 35 |
+
"confirmation_methods": [
|
| 36 |
+
"CGB agar",
|
| 37 |
+
"MALDI-TOF MS",
|
| 38 |
+
"MLST / molecular typing",
|
| 39 |
+
"ITS sequencing"
|
| 40 |
+
],
|
| 41 |
+
"treatment_notes": [
|
| 42 |
+
"Requires longer antifungal therapy than C. neoformans",
|
| 43 |
+
"Amphotericin B + flucytosine induction",
|
| 44 |
+
"Prolonged fluconazole consolidation phase",
|
| 45 |
+
"Surgical resection sometimes required for cryptococcomas"
|
| 46 |
+
],
|
| 47 |
+
"notes": "Major outbreak pathogen with environmental reservoirs in western Canada and the Pacific Northwest.",
|
| 48 |
+
"references": [
|
| 49 |
+
"C. gattii outbreak epidemiology",
|
| 50 |
+
"Treatment outcomes literature"
|
| 51 |
+
]
|
| 52 |
+
}
|